- Home
- SPFI vs OLMA Comparison
SPFI vs OLMA Comparison
Compare SPFI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- OLMA
- Stock Information
- Founded
- SPFI 1941
- OLMA 2006
- Country
- SPFI United States
- OLMA United States
- Employees
- SPFI N/A
- OLMA N/A
- Industry
- SPFI Major Banks
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- OLMA Health Care
- Exchange
- SPFI Nasdaq
- OLMA Nasdaq
- Market Cap
- SPFI 662.8M
- OLMA 725.5M
- IPO Year
- SPFI 2019
- OLMA 2020
- Fundamental
- Price
- SPFI $36.39
- OLMA $8.20
- Analyst Decision
- SPFI Buy
- OLMA Strong Buy
- Analyst Count
- SPFI 4
- OLMA 6
- Target Price
- SPFI $41.50
- OLMA $23.00
- AVG Volume (30 Days)
- SPFI 42.6K
- OLMA 1.4M
- Earning Date
- SPFI 10-23-2025
- OLMA 11-07-2025
- Dividend Yield
- SPFI 1.76%
- OLMA N/A
- EPS Growth
- SPFI 37.26
- OLMA N/A
- EPS
- SPFI 3.52
- OLMA N/A
- Revenue
- SPFI $205,251,000.00
- OLMA N/A
- Revenue This Year
- SPFI $13.43
- OLMA N/A
- Revenue Next Year
- SPFI $6.10
- OLMA N/A
- P/E Ratio
- SPFI $10.33
- OLMA N/A
- Revenue Growth
- SPFI 11.60
- OLMA N/A
- 52 Week Low
- SPFI $30.01
- OLMA $2.86
- 52 Week High
- SPFI $42.38
- OLMA $13.51
- Technical
- Relative Strength Index (RSI)
- SPFI 41.15
- OLMA 42.65
- Support Level
- SPFI $35.34
- OLMA $8.44
- Resistance Level
- SPFI $36.77
- OLMA $9.54
- Average True Range (ATR)
- SPFI 1.20
- OLMA 0.73
- MACD
- SPFI -0.10
- OLMA -0.16
- Stochastic Oscillator
- SPFI 29.33
- OLMA 37.70
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.